Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

24.86 +1.21 (+5.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Discover which S&P500 stocks are making waves on Friday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid
Via The Motley Fool
Exposures COVID-19
MRNA Q1 Earnings Call: Management Focuses on Cost Reductions and Pipeline Progress Amid Revenue Shortfall
Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2... 
Via StockStory
Exposures COVID-19
Earnings Scheduled For May 1, 2025
Via Benzinga
Preview: Moderna's Earnings
Via Benzinga
Stay informed with the top movers within the S&P500 index on Wednesday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers. 
Via Chartmill
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Exposures Product Safety
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves. 
Via Chartmill
What's going on in today's session: S&P500 movers
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Which S&P500 stocks are gapping on Tuesday?
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session. 
Via Chartmill
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program. 
Via Investor's Business Daily
Topics Government Intellectual Property
Exposures Intellectual Property Political
3 Cash-Heavy Stocks in the Doghouse
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
Topics Economy
Exposures COVID-19 Supply Chain
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Moderna reaffirms 2025 revenue guidance of $1.5 billion–$2.5 billion, cuts 2027 cost forecast by up to $1.7 billion, and targets 2026 approval for its flu/COVID combo shot. 
Via Benzinga
Exposures Product Safety
Thursday's session: gap up and gap down stock in the S&P500 index
Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Moderna Reports Q1 Revenue Drop, Warns Of Delay In Covid/Flu Vaccine Approval: Retail Sentiment Sours
The company reported first-quarter revenue of $108 million, down from $167 million in the corresponding period of 2024, and below an analyst estimate of $115.32 million, as per FinChat data. 
Via Stocktwits
Exposures COVID-19
These S&P500 stocks are moving in today's pre-market session
Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session. 
Via Chartmill
Moderna (NASDAQ:MRNA) Misses Q1 Revenue Estimates
Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2... 
Via StockStory
Exposures COVID-19
Moderna Misses Sales Forecasts, But Maintains Full-Year Outlook
The company is well known for its Covid vaccine. But sales came in below expectations. 
Via Investor's Business Daily
Topics Earnings Government
Exposures COVID-19 Financial Political
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting... 
Via Benzinga
Topics Government
Exposures COVID-19 Political Product Safety
Down 36%, Is Moderna a Buy on the Dip?
Via The Motley Fool
Exposures COVID-19 Product Safety
Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold
Via The Motley Fool
Exposures COVID-19
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
3 Healthcare Stocks Facing Headwinds
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback